Viridian Therapeutics, Inc. (VRDN)
NASDAQ: VRDN · Real-Time Price · USD
22.16
+0.09 (0.41%)
At close: Oct 24, 2025, 4:00 PM EDT
21.82
-0.34 (-1.53%)
After-hours: Oct 24, 2025, 7:56 PM EDT
Viridian Therapeutics Revenue
Viridian Therapeutics had revenue of $75.00K in the quarter ending June 30, 2025, with 4.17% growth. This brings the company's revenue in the last twelve months to $305.00K, up 5.90% year-over-year. In the year 2024, Viridian Therapeutics had annual revenue of $302.00K, down -3.82%.
Revenue (ttm)
$305.00K
Revenue Growth
+5.90%
P/S Ratio
5,933.65
Revenue / Employee
$2,133
Employees
143
Market Cap
1.81B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 302.00K | -12.00K | -3.82% |
| Dec 31, 2023 | 314.00K | -1.46M | -82.28% |
| Dec 31, 2022 | 1.77M | -1.19M | -40.20% |
| Dec 31, 2021 | 2.96M | 1.91M | 182.19% |
| Dec 31, 2020 | 1.05M | -3.41M | -76.46% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
VRDN News
- 3 days ago - Viridian Therapeutics Announces Pricing of $251 Million Public Offering of Shares of Common Stock - Business Wire
- 3 days ago - Viridian Therapeutics Announces Proposed Underwritten Public Offering - Business Wire
- 5 days ago - Viridian Therapeutics Announces Royalty Financing with DRI Healthcare for up to $300 Million - Business Wire
- 22 days ago - Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 4 weeks ago - Viridian Therapeutics: De-Risked Leadership In Thyroid Eye Disease - Seeking Alpha
- 5 weeks ago - Viridian Therapeutics Announces Completion of Enrollment in both REVEAL Clinical Trials and Positive Portfolio Updates - Business Wire
- 2 months ago - These Analysts Revise Their Forecasts On Viridian Therapeutics Following Q2 Results - Benzinga
- 2 months ago - Viridian Therapeutics Highlights Recent Progress and Reports Second Quarter 2025 Financial Results - Business Wire